Dual etiology vs. MetALD: how MAFLD and MASLD address liver diseases coexistence

Abstract

Fatty liver disease associated with metabolic dysfunction has emerged as a significant global health challenge. This condition often coexists with other liver diseases, such as alcohol-related liver disease and viral hepatitis, complicating both diagnosis and management. To address the limitations of the non-alcoholic fatty liver disease (NAFLD) classification, two alternative frameworks have been proposed: metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020 and metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023. A key difference between these definitions is how they consider fatty liver disease in relation to the coexistence of other liver conditions. MAFLD adopts a dual etiology concept, creating a unified classification system that aligns with contemporary clinical and epidemiological needs. In contrast, MASLD introduces a new term, MetALD (metabolic and alcohol-related/associated liver disease), to describe patients who have both metabolic dysfunction and excessive alcohol intake. This review critically examines the clinical, research, and epidemiological implications of the differing approaches of MAFLD and MASLD, offering insights into their potential to enhance the understanding and management of multi-etiology liver diseases.

Keywords

MAFLD / NAFLD / MASLD / dual etiology / MetALD

References

[1] Chan KE,Tang ASP.Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals.J Clin Endocrinol Metab2022;107:2691-700

[2] Eslam M,Francque S.Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight.Nat Rev Gastroenterol Hepatol2022;19:638-51

[3] Eslam M,Yu ML.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease.Hepatol Int2025;

[4] Eslam M,Després JP.Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases.Lancet Gastroenterol Hepatol2021;6:743-53

[5] Ludwig J,McGill DB.Nonalcoholic steatohepatitis Mayo Clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[6] Yilmaz Y.The heated debate over NAFLD renaming: an ongoing saga.Hepatol Forum2023;4:89-91 PMCID:PMC10564248

[7] Eslam M,Mendez-Sanchez N.Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health.Lancet Gastroenterol Hepatol2020;5:713-5

[8] Byrne CD.MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?.Metab Target Organ Damage2024;4:10

[9] Eslam M.Two years on, a perspective on MAFLD.eGastroenterology2023;1:e100019 PMCID:PMC11770426

[10] Eslam M,Vajro P.Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.Lancet Gastroenterol Hepatol2021;6:864-73

[11] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[12] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.

[13] Eslam M,Wong VW.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.Hepatol Int2020;14:889-919

[14] Fouad Y,Alboraie M.What the new definition of MASLD left behind: dual etiology with viral hepatitis.Clin Gastroenterol Hepatol2024;22:1751-2

[15] Méndez-Sánchez N, Bugianesi E, Gish RG, et al; Global multi-stakeholder consensus on the redefinition of fatty liver disease. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388-90.

[16] Alharthi J,Cua IH,Eslam M.Metabolic dysfunction-associated fatty liver disease: a year in review.Curr Opin Gastroenterol2022;38:251-60

[17] Alboraie M,Xu X.Global multi-societies endorsement of the MAFLD definition.Ann Hepatol2024;29:101573

[18] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.

[19] Fan JG, Xu XY, Yang RX, et al; Chinese Society of Hepatology, Chinese Medical Association. Guideline for the prevention and treatment of metabolic dysfunction-associated fatty liver disease (version 2024). J Clin Transl Hepatol. 2024;12:955-74. PMCID:PMC11557364

[20] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[21] Díaz LA,Louvet A,Arrese M.The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease.Nat Rev Gastroenterol Hepatol2023;20:764-83

[22] Tourkochristou E,Thomopoulos K,Triantos C.NAFLD and HBV interplay - related mechanisms underlying liver disease progression.Front Immunol2022;13:965548 PMCID:PMC9760931

[23] Zheng Q,Wu Y.Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B.Aliment Pharmacol Ther2021;54:1100-9

[24] Zhang M,Wu X.Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection.J Med Virol2023;95:e29156

[25] Patmore LA,van der Spek D.Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B.Clin Gastroenterol Hepatol2023;21:3089-96.e1

[26] Lin S,Liu Y.Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease.Clin Res Hepatol Gastroenterol2021;45:101483

[27] Attia D,El-Akel W.Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study.Aliment Pharmacol Ther2022;56:1581-90

[28] Cheng KL,Cheng YM,Wang CC.Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease.J Formos Med Assoc2024;123:36-44

[29] Lonardo A,Loria P,Ruggiero G.Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease.Gastroenterology2004;126:586-97

[30] Huang CF,Yeh ML.Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection.J Hepatol2015;62:512-8

[31] Younossi ZM,Ong JP.Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.J Clin Gastroenterol2004;38:705-9

[32] Khattab MA,Mousa YI.Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma.Ann Hepatol2012;11:487-94

[33] Eslam M,Del Campo JA,Khattab MA.Use of HOMA-IR in hepatitis C.J Viral Hepat2011;18:675-84

[34] Lonardo A,Restivo L.Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.World J Gastroenterol2014;20:7089-103 PMCID:PMC4064057

[35] Wong RJ,Sinha SR,Ahmed A.Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes.J Community Health2014;39:437-45

[36] Shih CI,Hsieh MH.Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study.Hepatol Int2024;18:138-54

[37] Yu ML.Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the Nobel prize in physiology or medicine 2020.Kaohsiung J Med Sci2021;37:7-11

[38] Liu CJ,Yu ML.Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.Hepatol Int2024;18:897-908

[39] Carvalho AF,Perez A,Rehm J.Alcohol use disorders.Lancet2019;394:781-92

[40] Åberg F,Salomaa V.Combined effects of alcohol and metabolic disorders in patients with chronic liver disease.Clin Gastroenterol Hepatol2020;18:995-7.e2

[41] Chang Y,Kim Y.Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study.Hepatology2019;69:64-75

[42] Tian C,Kershenobich D,Hinds DA.Variant in PNPLA3 is associated with alcoholic liver disease.Nat Genet2010;42:21-3

[43] Petrie E,Bril F.Metabolic characteristics of patients with MetALD: caveats of a new definition.Liver Int2024;44:2929-38

[44] Alboraie M,Piscoya A.Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in metabolic dysfunction-associated liver diseases.Med Sci Monit2024;30:e945198 PMCID:PMC11299466

[45] Holbeck M,Singal AK.Integrated multidisciplinary management of alcohol-associated liver disease.J Clin Transl Hepatol2023;11:1404-12 PMCID:PMC10500286

[46] Musto JA,Lucey MR.Is there a safe limit for consumption of alcohol?.J Hepatol2025;82:535-40 PMCID:PMC11830546

[47] Meijnikman AS,Schnabl B.Endogenous ethanol production in health and disease.Nat Rev Gastroenterol Hepatol2024;21:556-71

[48] Boniface S,Shelton N.Drinking pattern is more strongly associated with under-reporting of alcohol consumption than socio-demographic factors: evidence from a mixed-methods study.BMC Public Health2014;14:1297 PMCID:PMC4320509

[49] Joo EJ,Yeom JS.Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study.Hepatology2017;65:828-35

[50] Seto WK.Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies.World J Gastroenterol2019;25:282-6 PMCID:PMC6343097

[51] Wong VW,Chu WC.Hepatitis B virus infection and fatty liver in the general population.J Hepatol2012;56:533-40

[52] Sarin SK,Eslam M.Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission.Lancet Gastroenterol Hepatol2020;5:167-228 PMCID:PMC7164809

[53] Huang JF,Hwang SJ.Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication.Am J Gastroenterol2007;102:1237-43

[54] van Kleef LA,Brouwer WP.Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.JHEP Rep2021;3:100350 PMCID:PMC8446794

[55] Manzano-Nunez R,Navarro J.Uncovering the NAFLD burden in people living with HIV from high- and middle-income nations: a meta-analysis with a data gap from Subsaharan Africa.J Int AIDS Soc2023;26:e26072 PMCID:PMC10018385

[56] Díaz LA,Arnold J.Liver diseases in latin america: current status, unmet needs, and opportunities for improvement.Curr Treat Options Gastroenterol2022;20:261-78 PMCID:PMC9202671

[57] Müller L. Integrated approaches in chronic disease management: a new model for internal medicine. Arch Med. 2025;17:001-2. Available from: https://www.itmedicalteam.pl/articles/integrated-approaches-in-chronic-disease-management-a-new-model-for-internal-medicine.pdf [Last accessed on 27 Mar 2025].

[58] Okpujie V,Uwumiro F.The influence of insulin resistance on outcomes in hospitalizations for alcohol-related liver disease: a nationwide study.Cureus2023;15:e42964 PMCID:PMC10475319

[59] Kernick D,O’Flynn N.Clinical assessment and management of multimorbidity: NICE guideline.Br J Gen Pract2017;67:235-6 PMCID:PMC5409424

[60] Fernandez CJ,Afsar H.Metabolic dysfunction-associated fatty liver disease and chronic viral hepatitis: the interlink.Pathogens2024;13:68 PMCID:PMC10821334

[61] Zhang H, Targher G, Byrne CD, et al; MAFLD ICD-11 coding collaborators. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2024;18:1178-201.

[62] Zhou XD, Lonardo A, Pan CQ, Shapiro MD, Zheng MH; WMU MAFLD Clinical Research Working Group. Clinical features and long-term outcomes of patients diagnosed with MASLD, MAFLD, or both. J Hepatol. 2024;81:e157-9.

[63] Åberg F,Pirola CJ,Sookoian S.Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease.J Hepatol2023;78:191-206

[64] Pan Z,Yu ML.MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.Ther Adv Endocrinol Metab2024;15:20420188241252543 PMCID:PMC11131400

[65] Pan Z,Abdulla M,Sebastiani G.MAFLD identifies patients with significant hepatic fibrosis better than MASLD.Hepatol Int2024;18:964-72

[66] Pan Z, Eslam M; panel of collaborators. The MASLD criteria overlook a number of adolescent patients with severe steatosis. J Hepatol. 2024;81:e80-1.

[67] Pan Z,Esmat G,Eslam M.MAFLD predicts cardiovascular disease risk better than MASLD.Liver Int2024;44:1567-74

[68] Pan Z,AlNaamani K,Fan JG.MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.Ann Hepatol2024;29:101512

[69] Hoang T,Kim BH,Kim J.Evaluation of nomenclature of fatty liver disease in association with hepatocellular carcinoma: a 14.5-year cohort study in Korea.Cancer Res Treat2025;Epub ahead of print:

[70] Vaz K,Majeed A.MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study.Hepatol Int2024;Epub ahead of print:

[71] Jiang M,George J.Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.Hepatol Int2024;18:1731-9

[72] Pan Z,Al-Busafi SA.The MAFLD definition identifies three homogenous groups of patients.Liver Int2024;44:3287-9

[73] Zhao Q.Comparison of mortality outcomes in individuals with MASLD and/or MAFLD.J Hepatol2024;80:e62-4

[74] Lonardo A,Caldwell SH.Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature.J Hepatol2024;80:e192-4